There are conflicting guidelines regarding when to screen cholesterol levels in young adults. A new study aims to clarify at what age asymptomatic individuals should be screened to calculate their elevated risk of developing atherosclerotic cardiovascular disease.
While global inequalities for survival of childhood leukemia have narrowed, the gap remains wide for acute lymphoblastic leukemia and acute myeloid leukemia, according to a study published in The Lancet Haematology. In some countries, the 5-year survival rate is nearly twice as high as in others for children diagnosed in 2005-2009.
The United States healthcare system has to start spending less time fixing people and more time and money on reducing the need to fix them by getting to people earlier, according to panelists who participated in the Brookings Institution’s event “New Directions for Communities: How They Can Boost Neighborhood Health.”
The Senate has confirmed Scott Gottlieb, MD, for the position of FDA Commissioner. Gottlieb faced some criticism from Democrats for his close ties to the pharmaceutical industry, but he promised to recuse himself from any FDA decisions relating to some 20 companies and institutions for 1 year.
A day after House Republicans voted to pass legislation that repeals and replaces large parts of the Affordable Care Act, Avik Roy, Forbes opinion editor and president of the Foundation for Research on Equal Opportunity, outlined what Republicans are trying to fix. After his presentation, he joined a panel discussion on what impact the American Health Care Act will have.
Panelists on day 1 of the ACO & Emerging Healthcare Delivery Coalition® discussed the challenging work of creating public-private partnerships, and how these initiatives can address issues to improve the health of a population.
Patients with irritable bowel syndrome with diarrhea (IBS-D) incur significantly more healthcare costs than matched controls. A new study in the Journal of Managed Care & Specialty Pharmacy found that the extra costs were associated with an increased use of medical services.
When the ACO & Emerging Healthcare Delivery Coalition® meets May 4-5 in Scottsdale, Arizona, attendees will learn the latest on healthcare reform, best practices for cybersecurity, population health strategies, and more.
Second primary malignant neoplasms (SPMs) are a well-known late effect after cancer, and a new study has found that they are more deadly among children and young adults than older adults.
A study in Journal of Medical Internet Research sought to discover how technologies could encourage daily walking in this population. The researchers developed 3 prototype apps using different persuasive technology design principles: dialogue support, primary task support, and social support.
A new predictive model that relies primarily on patient demographics was able to improve predictive accuracy of identifying high-cost patients in the future at Intermountain Healthcare. The results of the study and the specifics of the model were published in >eGEMs.
Despite the wide variety of rare diseases out there, children and families living with rare disease have one thing in common: they experience diagnostic delays. A new study in Orphanet Journal of Rare Diseases described experiences of seeking and receiving a diagnosis of a rare disease and access to healthcare.
The European Respiratory Society and the American Thoracic Society have conducted a comprehensive review of evidence of managing exacerbations of chronic obstructive pulmonary disease in order to create a guideline of clinical recommendations.
People with high cholesterol, a known risk factor for heart disease and stroke, aren’t sure how to manage their condition, while 47% of people who had a history of cardiovascular disease or stroke had not checked their cholesterol in the past year.
Considering people spend two-thirds of their lives where they live, the quality of housing and the state of their neighborhood can play a large role in well-being and cause poor health. A new report from Urban Institute took a look at the impact of blighted properties and policy and program recommendations that can help communities make housing and neighborhoods healthier.
A new study in the Annals of Family Medicine, compared 11 countries and found that the US has the highest rate of poor primary care coordination. In order to better care for a growing younger, chronically ill population, the US healthcare system will need to be redesigned, the authors concluded.
Following a partisan battle and a year of contention following the death of Anton Scalia, the Senate has confirmed Neil Gorsuch to the Supreme Court of the United States. With nearly all Democrats voting against confirmation, the Senate voted along party lines to eliminate the filibuster for Supreme Court confirmations so Gorsuch could be confirmed with only 54 senators supporting him.
Clinical pathways can successfully be used to drive physicians to choose a less costly regimen when the efficacy and toxicity of different treatment regimens for metastatic colorectal cancer are comparable, according to a study in the Journal of Oncology Practice.
The patient voice is becoming more important as healthcare moves to a value-based, patient-centered system of care, but just amplifying the patient voice is not enough. There needs to not only be amplification, but also a constructive response from the health system, said Thomas Lee, MD, chief medical officer at Press Ganey, during his presentation at the National Quality Forum Annual Conference.
Panelists, during a session on value and value-based reimbursement at the Academy of Managed Care Pharmacy Annual Meeting, held March 27-30 in Denver, Colorado, discussed the benefits and challenges of value-based contracting and the current and evolving use of value frameworks.
Since the Republican bill to repeal and replace Obamacare never made it to a vote, insurers are still very uncertain about the future of healthcare. At this time it is unclear whether Republicans plan to shore up the law or actively undermine it.
Patients with chronic obstructive pulmonary disease see benefits from physical activity (PA); however, there are several barriers that limit participation in PA in a primary care setting.
Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), discusses what the FDA would look like with Scott Gottlieb, MD, as commissioner, how the fee scheme of pharmacy benefit managers are contributing to rising drug costs, and COA's upcoming conference.
At the Academy of Managed Care Pharmacy (AMCP) Annual Meeting, held March 27-30, 2017, in Denver, Colorado, the cost of healthcare was on everyone’s minds and was a common thread in most sessions.
New targeted therapies reduce waste and identify patients that will benefit most, but their high price tags have left the healthcare industry scrambling to figure out how to pay for these treatments and cures.
In a session covering the future of the business of healthcare in the United States, Kevin Grabenstatter, managing director for L.E.K. Consulting, asserted that healthcare is an unsustainably big business, which means that change is coming.
The move away from fee-for-service has driven some health plans to embrace value-based care contracts and accountable care organizations. During a session at the Academy of Managed Care Pharmacy Annual Meeting, held March 27-30, 2017, in Denver, Colorado, panelists outlined how the marketplace has evolved.
The Academy of Managed Care Pharmacy Annual Meeting kicked off on March 28, 2017, in Denver, Colorado, with a look at the specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
The majority of costs associated with chronic obstructive pulmonary disease (COPD) are associated with hospitalizations, and a new study in the International Journal of COPD set out to determine the exact drivers of high costs among hospitalized patients with COPD.
While the orphan drug market has been growing, a new study argues that the current unmet needs of patients with rare disease proves that current incentives are not efficiently stimulating orphan drug development.
